Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission ...
American Association of Individual Investors

Why Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 15.15%

As of Thursday, January 08, Phathom Pharmaceuticals, Inc.’s PHAT share price has dipped by 15.15%, which has investors ...

Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvem ...
The Manila Times

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvem…

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete ...

Phathom Pharma Shows Sales Strength, Targets 2026 Profitability

Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.